Resveratrol in cancer management: Where are we and where we go from here?

Annals of the New York Academy of Sciences

Volumn 1215, Issue 1, 2011, Pages 144-149

  Ndiaye, Mary ^a   Kumar, Raj ^b   Ahmad, Nihal ^a,c  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b Janet Weis Children s Hospital   (United States)

^c UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Bioavailability; Nanoparticles; Piceatannol; Resveratrol

Indexed keywords

ANDROGEN; CURCUMIN; DRUG METABOLITE; ESTROGEN; GLUCURONIDE; MYRICETIN; NANOCARRIER; PICEATANNOL; PIPERINE; POLYPHENOL; QUERCETIN; RESVERATROL; SULFATE; SULFOTRANSFERASE; URIDINE DIPHOSPHATE GLUCURONIC ACID;

ARTICLE; BREAST CANCER; CHEMICAL MODIFICATION; CHEMOPROPHYLAXIS; COLORECTAL CANCER; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG CONJUGATION; DRUG EFFICACY; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG SAFETY; DRUG SOLUBILITY; DRUG TISSUE LEVEL; FOOD DRUG INTERACTION; GRAPE JUICE; HUMAN; HYDROGENATION; IC 50; NANOTECHNOLOGY; NONHUMAN; PROTEIN EXPRESSION; TARGET ORGAN; WINE;

MAMMALIA;

EID: 78851469731     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05851.x     Document Type: Article

References (62)

1. Aziz, M.H. et al 2005. Chemoprevention of skin cancer by grape constituent resveratrol: relevance to human disease? FASEB J. 19: 1193-1195.
2. Reagan-Shaw, S., H. Mukhtar & N. Ahmad 2008. Resveratrol imparts photoprotection of normal cells and enhances the efficacy of radiation therapy in cancer cells. Photochem. Photobiol. 84: 415-421.
3. Afaq, F. et al 2002. Botanical antioxidants for chemoprevention of photocarcinogenesis. Front. Biosci. 7: d784-d792.
4. Shankar, S., G. Singh & R.K. Srivastava 2007. Chemoprevention by resveratrol: molecular mechanisms and therapeutic potential. Front. Biosci. 12: 4839-4854.
5. Bhat, K.P. & J.M. Pezzuto 2002. Cancer chemopreventive activity of resveratrol. Ann. N. Y. Acad. Sci. 957: 210-229.
6. Gullett, N.P. et al 2010. Cancer prevention with natural compounds. Semin. Oncol. 37: 258-281.
7. Aziz, M.H., R. Kumar & N. Ahmad 2003. Cancer chemoprevention by resveratrol: in vitro and in vivo studies and the underlying mechanisms (review). Int. J. Oncol. 23: 17-28.
8. Baur, J.A. & D.A. Sinclair 2006. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov. 5: 493-506.
9. Renaud, S. & M. de Lorgeril 1992. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 339: 1523-1526.
10. Nonomura, S., H. Kanagawa & A. Makimoto 1963. [Chemical Constituents of Polygonaceous Plants. I. Studies on the Components of Ko-J O-Kon. (Polygonum Cuspidatum Sieb. Et Zucc.)]. Yakugaku Zasshi. 83: 988-990.
11. Clement, M.V. et al 1998. Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells. Blood 92: 996-1002.
12. Jang, M. et al 1997. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218-220.
13. Aziz, M.H., F. Afaq & N. Ahmad 2005. Prevention of ultraviolet-B radiation damage by resveratrol in mouse skin is mediated via modulation in surviving. Photochem. Photobiol. 81: 25-31.
14. Aziz, M.H. et al 2006. Resveratrol-caused apoptosis of human prostate carcinoma LNCaP cells is mediated via modulation of phosphatidylinositol 3'-kinase/Akt pathway and Bcl-2 family proteins. Mol. Cancer Ther. 5: 1335-1341.
15. Reagan-Shaw, S. et al 2004. Modulations of critical cell cycle regulatory events during chemoprevention of ultraviolet B-mediated responses by resveratrol in SKH-1 hairless mouse skin. Oncogene 23: 5151-5160.
16. Bishayee, A. 2009. Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev. Res. (Phila Pa). 2: 409-418.
17. Afaq, F., V.M. Adhami & N. Ahmad 2003. Prevention of short-term ultraviolet B radiation-mediated damages by resveratrol in SKH-1 hairless mice. Toxicol. Appl. Pharmacol. 186: 28-37.
18. Ahmad, K.A. et al 2004. Resveratrol inhibits drug-induced apoptosis in human leukemia cells by creating an intracellular milieu nonpermissive for death execution. Cancer Res. 64: 1452-1459.
19. Ahmad, K.A. et al 2007. Protein kinase CK2 modulates apoptosis induced by resveratrol and epigallocatechin-3-gallate in prostate cancer cells. Mol. Cancer Ther. 6: 1006-1012.
20. Dong, Z. 2003. Molecular mechanism of the chemopreventive effect of resveratrol. Mutat. Res. 523-524: 145-150.
21. Saiko, P. et al 2008. Resveratrol and its analogs: defense against cancer, coronary disease and neurodegenerative maladies or just a fad? Mutat. Res. 658: 68-94.
22. Boocock, D.J. et al 2007. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol. Biomarkers Prev. 16: 1246-1252.
23. Walle, T. et al 2004. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos. 32: 1377-1382.
24. Wenzel, E. & V. Somoza 2005. Metabolism and bioavailability of trans-resveratrol. Mol. Nutr. Food Res. 49: 472-481.
25. Burkon, A. & V. Somoza 2008. Quantification of free and protein-bound trans-resveratrol metabolites and identification of trans-resveratrol-C/O-conjugated diglucuronides - two novel resveratrol metabolites in human plasma. Mol. Nutr. Food Res. 52: 549-557.
26. Almeida, L. et al 2009. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol. Nutr. Food Res. 53(Suppl 1): S7-S15.
27. Nunes, T. et al 2009. Pharmacokinetics of trans-resveratrol following repeated administration in healthy elderly and young subjects. J. Clin. Pharmacol. 49: 1477-1482.
28. Vaz-da-Silva, M. et al 2008. Effect of food on the pharmacokinetic profile of trans-resveratrol. Int. J. Clin. Pharmacol. Ther. 46: 564-570.
29. Cottart, C.H. et al 2010. Resveratrol bioavailability and toxicity in humans. Mol. Nutr. Food Res. 54: 7-16.
30. Patel, K.R. et al 2010. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res. 70: 7392-7399.
31. Brown, V.A. et al 2010. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics and effect on the insulin-like growth factor axis. Cancer Res. Advance online publication. doi:.
32. Reen, R.K. et al 1993. Impairment of UDP-glucose dehydrogenase and glucuronidation activities in liver and small intestine of rat and guinea pig in vitro by piperine. Biochem. Pharmacol. 46: 229-238.
33. Atal, C.K., R.K. Dubey & J. Singh 1985. Biochemical basis of enhanced drug bioavailability by piperine: evidence that piperine is a potent inhibitor of drug metabolism. J. Pharmacol. Exp. Ther. 232: 258-262.
34. Srinivasan, K. 2007. Black pepper and its pungent principle-piperine: a review of diverse physiological effects. Crit. Rev. Food. Sci. Nutr. 47: 735-748.
35. Lambert, J.D. et al 2004. Piperine enhances the bioavailability of the tea polyphenol (-)-epigallocatechin-3-gallate in mice. J. Nutr. 134: 1948-1952.
36. de Santi, C. et al 2000. Glucuronidation of resveratrol, a natural product present in grape and wine, in the human liver. Xenobiotica 30: 1047-1054.
37. De Santi, C. et al 2000. Sulphation of resveratrol, a natural compound present in wine, and its inhibition by natural flavonoids. Xenobiotica 30: 857-866.
38. De Santi, C. et al 2000. Sulphation of resveratrol, a natural product present in grapes and wine, in the human liver and duodenum. Xenobiotica 30: 609-617.
39. Mikstacka, R., A.M. Rimando & E. Ignatowicz 2010. Antioxidant effect of trans-resveratrol, pterostilbene, quercetin and their combinations in human erythrocytes in vitro. Plant. Foods Hum. Nutr. 65: 57-63.
40. la Porte, C. et al 2010. Steady-State pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. Clin. Pharmacokinet. 49: 449-454.
41. Siddiqui, I.A. et al 2010. Nanochemoprevention: sustained release of bioactive food components for cancer prevention. Nutr. Cancer. 62: 883-890.
42. Lu, X. et al 2009. Resveratrol-loaded polymeric micelles protect cells from Abeta-induced oxidative stress. Int. J. Pharm. 375: 89-96.
43. Shao, J. et al 2009. Enhanced growth inhibition effect of resveratrol incorporated into biodegradable nanoparticles against glioma cells is mediated by the induction of intracellular reactive oxygen species levels. Colloids Surf. B. Biointerfaces 72: 40-47.
44. Teskac, K. & J. Kristl 2010. The evidence for solid lipid nanoparticles mediated cell uptake of resveratrol. Int. J. Pharm. 390: 61-69.
45. Guo, L. et al 2010. Anticancer activity and molecular mechanism of resveratrol-bovine serum albumin nanoparticles on subcutaneously implanted human primary ovarian carcinoma cells in nude mice. Cancer Biother. Radiopharm. 25: 471-477.
46. Narayanan, N.K. et al 2009. Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice. Int. J. Cancer. 125: 1-8.
47. Szekeres, T. et al 2010. Resveratrol and resveratrol analogues-structure-activity relationship. Pharm. Res. 27: 1042-1048.
48. Ferrigni, N.R. et al 1984. Use of potato disc and brine shrimp bioassays to detect activity and isolate piceatannol as the antileukemic principle from the seeds of Euphorbia lagascae. J. Nat. Prod. 47: 347-352.
49. Potter, G.A. et al 2002. The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Br. J. Cancer 86: 774-778.
50. Kim, E.J. et al 2009. The grape component piceatannol induces apoptosis in DU145 human prostate cancer cells via the activation of extrinsic and intrinsic pathways. J. Med. Food 12: 943-951.
51. Lee, Y.M. et al 2009. Piceatannol, a natural stilbene from grapes, induces G1 cell cycle arrest in androgen-insensitive DU145 human prostate cancer cells via the inhibition of CDK activity. Cancer Lett. 285: 166-173.
52. Vo, T.P. et al 2009. Pro- and anti-carcinogenic mechanisms of piceatannol are activated dose-dependently in MCF-7 breast cancer cells. Carcinogenesis. Advance online publication. doi:.
53. Kuo, P.L. & Y.L. Hsu 2008. The grape and wine constituent piceatannol inhibits proliferation of human bladder cancer cells via blocking cell cycle progression and inducing Fas/membrane bound Fas ligand-mediated apoptotic pathway. Mol. Nutr. Food Res. 52: 408-418.
54. Son, P.S. et al 2010. Piceatannol, a catechol-type polyphenol, inhibits phorbol ester-induced NF-{kappa}B activation and cyclooxygenase-2 expression in human breast epithelial cells: cysteine 179 of IKK{beta} as a potential target. Carcinogenesis 31: 1442-1449.
55. Ruweler, M. et al 2009. Cytotoxic, cytoprotective and antioxidant activities of resveratrol and analogues in C6 astroglioma cells in vitro. Chem. Biol. Interact. 182: 128-135.
56. Horvath, Z. et al 2007. Novel resveratrol derivatives induce apoptosis and cause cell cycle arrest in prostate cancer cell lines. Anticancer Res. 27: 3459-3464.
57. Saiko, P. et al 2007. N-hydroxy-N'-(3, 4, 5-trimethoxyphenyl)-3, 4, 5-trimethoxy-benzamidine, a novel resveratrol analog, inhibits ribonucleotide reductase in HL-60 human promyelocytic leukemia cells: synergistic antitumor activity with arabinofuranosylcytosine. Int. J. Oncol. 31: 1261-1266.
58. Sun, B. et al 2010. Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg. Med. Chem. 18: 5352-5366.
59. Bertini, S. et al 2010. Synthesis of heterocycle-based analogs of resveratrol and their antitumor and vasorelaxing properties. Bioorg. Med. Chem. 18: 6715-6724.
60. Biasutto, L. et al 2009. Soluble polyphenols: synthesis and bioavailability of 3, 4', 5-tri(alpha-D-glucose-3-O-succinyl) resveratrol. Bioorg. Med. Chem. Lett. 19: 6721-6724.
61. Reagan-Shaw, S., M. Nihal & N. Ahmad 2008. Dose translation from animal to human studies revisited. FASEB J. 22: 659-661.
62. Hoshino, J. et al 2010. Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites. J. Med. Chem. 53: 5033-5043.